Compare ADVB & TNON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADVB | TNON |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 9.8M |
| IPO Year | 2025 | 2022 |
| Metric | ADVB | TNON |
|---|---|---|
| Price | $0.26 | $0.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 38.4K | ★ 83.0K |
| Earning Date | 02-18-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,233,000.00 |
| Revenue This Year | N/A | $19.56 |
| Revenue Next Year | N/A | $71.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.25 | $0.72 |
| 52 Week High | $4.10 | $5.85 |
| Indicator | ADVB | TNON |
|---|---|---|
| Relative Strength Index (RSI) | 35.78 | 19.21 |
| Support Level | $0.25 | $0.93 |
| Resistance Level | $0.35 | $0.97 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 12.17 | 3.18 |
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.